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Supplementary Methods 
 
(a) Further details of population 
We included Escherichia coli isolated from blood from pure and mixed/polymicrobial cultures in our primary 
outcome in case differences in identification of polymicrobial infections were affecting incidence trends. 
Mixed/polymicrobial cultures comprised 763/5706 (13%) EC-BSI over the study. Of these, 187/763 (25%) were 
infections with E. coli and only plausible contaminants, including Coagulase negative staphylococcus; 
Streptococcus viridans, oralis, salivarius, mitis, viridans, and unspecified; diphtheroids; Propionibacterium 
species; and Bacillus species. Of the 576 EC-BSI with at least one other plausible pathogen, 412 (72%) other 
pathogens were likely gastrointestinal including Klebsiella pneumoniae and oxytoca, Enterococcus species, 
Enterococcus faecalis group D, Proteus mirabilis, Bacteroides fragilis, Enterobacter species, gastrointestinal 
anaerobes, and yeast. Percentages of polymicrobial infections did not vary over calendar time. 
 
We used a strict definition of nosocomial EC-BSI ending at discharge in order to investigate the group whose 
EC-BSI had not actually been identified during hospitalisation. A relatively small number, 44/1132 (4%), of 
quasi-nosocomial EC-BSI cases were discharged in the 24 hours preceding the blood culture being taken: 
147/1132 (13%) were discharged in the last 48 hours. 
 
(b) Further details of classifications 
Urinary specimens should only be sent for microbiological testing on clinical suspicion of a UTI;1 however, 
43% of mixed growth or culture-negative urine samples taken within [-30,+2] days of an E. coli bloodstream 
infection (EC-BSI) did not have a completed request code making it difficult to assess whether there really was 
clinicial suspicion of urinary infection before the bacteraemia. To investigate the contribution of antecedent 
UTIs to rising E. coli bacteraemia incidence, we therefore hierarchically classified E. coli bacteraemias as  
(i) ‘likely urine-associated’, if they either had an E. coli-positive urine culture, or if they had mixed 
growth or negative urine culture with a relevant request code (mentioning UTI or other urinary 
symptoms, dysuria, urosepsis, pyelonephritis, positive dipstick), within [-30,-3] days of the EC-BSI 
sample 
(ii) ‘urosepsis’, if they either had an E. coli-positive urine culture, or if they had mixed growth or negative 
urine culture with a relevant request code within (-3,+2] days of the bacteraemia sample (but not (i), i.e. 
no pre-existing evidence of a urine infection which could have potentially been prevented from 
becoming urosepsis) 
(iii) ‘unlikely urine-associated’, if they had a urine culture positive for other pathogens within [-30,+2] days 
of the EC-BSI sample, or if no urine culture was taken within [-30,+2] days of the EC-BSI sample (but 
not (i) or (ii)) 
(iv) ‘unknown’, if they had a mixed growth or negative urine culture and either an irrelevant or no request 
code within [-30,+2] days of the EC-BSI sample (but not (i), (ii) or (iii))). 
Sensitivity analyses included definitions based on urine cultures up to 100 days before the EC-BSI sample rather 
than 30 days, with similar results (data not shown). 
 
For quasi-nosocomial bacteraemias, primary diagnostic codes from the antecedent admission were grouped as 
‘cardiovascular disorder’, ‘neurological disorder’, ‘dermatological/rheumatological disorders’, ‘endocrine 
disorder’, ‘obstetrics and gynaecology disorder’, ‘haematological disorder’, ‘malignancy’, ‘gastrointestinal 
disorder’, ‘orthopaedic disorders including trauma’, ‘poisoning’, ‘renal and urological disorders’, ‘respiratory 
disorder’, ‘other’.2 
 
(c) Antimicrobial susceptibility testing 
To investigate AMR burden, we assessed E. coli isolated from blood for resistance reported by the diagnostic 
laboratory to amoxicillin, co-amoxiclav, trimethoprim, gentamicin, ciprofloxacin, ceftriaxone, ceftazidime, 
piperacillin-tazobactam and meropenem, and E. coli isolated from urine for resistance to amoxicillin, co-
amoxiclav, trimethoprim, ciprofloxacin, nitrofurantoin and cefalexin (the only drugs consistently tested 
throughout the study period). Before February 2013, in the OUH microbiology service laboratory antimicrobial 
susceptibility was tested using disk diffusion in an uncontrolled inoculum using a control; in February 2013 this 
was replaced by the automated susceptibility testing with the Phoenix BD system using European Committee on 
Antimicrobial Susceptibility testing (EUCAST) breakpoints, using disk diffusion direct from blood in an 
uncontrolled inoculum as an early flag. In December 2013, disk diffusion in a controlled inoculum using the 
British Society for Antimicrobial Chemotherapy (BSAC) diameter zones was introduced for selected samples in 
addition to BD-Phoenix. Where multiple results were available for one sample, the Phoenix result was used in 
preference to the disk diffusion result as most disk diffusion results were uncontrolled; otherwise any resistant 
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result was used in preference to susceptible results. Agreement between disk diffusion and Phoenix in samples 
where both were done was reasonable (Supplementary Figure 14). 
 
(d) Changes in co-amoxiclav formulation in hospital prescribing 
In July 2010, the hospital co-amoxiclav formulation changed from 250mg amoxicillin and 125mg clavulanate to 
500mg amoxicillin and 125mg clavulanate affecting defined daily doses (DDD) because of the different 
strengths. Hospital practice was to prescribe an additional 250mg amoxicillin with the original formulation prior 
to July 2010, supported by a concurrent decrease in raw amoxicillin DDDs in July 2010 (because it was no 
longer being prescribed with the original co-amoxiclav formulation) and increase in co-amoxiclav DDDs in July 
2010 (as an additional 250mg amoxicillin was being counted as a co-amoxiclav DDD rather than an amoxicillin 
DDD). We therefore adjusted raw co-amoxiclav and amoxicillin DDDs before July 2010 to count the additional 
amoxicillin prescribed with the old co-amoxiclav formulation as a co-amoxiclav DDD, making assignment 
consistent over the whole study period.  
 
(e) Further details of statistical analyses 
Changes in trends in outcomes were estimated using iterative sequential regression (ISR).3 The ISR algorithm 
first modelled the outcome using samples taken between 1 January 1998 and 1 January 1999, and compared a 
model with one trajectory over calendar time in the outcome to a model allowing this trajectory to change 6 
months after the start of observation. If the model with two trajectories was not a better fit (determined by a 
Bayesian Information Criterion being lower by at least 3.84 [the critical value to detect a significance level of 
0.05 with a χ2 test and one degree of freedom]), an additional six month’s observations (to June 1999) were 
included. Then the model with one trajectory was compared to models with 2 trajectories with either June 1998 
or January 1999 as the changepoint, again considering whether any model with a change in trajectory 
substantially improved model fit. Any changepoint that improved model fit was fixed, and then an additional six 
month’s data included. This process was iterated up to January 2017. For antibiotic resistance trends, due to the 
smaller number of observations counts per year (rather than per month) were modelled, first considering 
samples taken between 1 January 1998 and 1 January 2002, and then successively every year through 1 January 
2017. Incidence trends in different subgroups, or for different outcomes, were compared using stacked 
regression.4 In brief, these methods “stack” the data for different regression models, for example for EC-BSI 
incidence in each of the four different healthcare exposure subgroups over calendar time, on top of each other. 
Individual model-specific trends are then calculated but across the entire stacked dataset, using robust variance 
adjustment to account for the same dependent variable (here month) occurring repeatedly in the stacked dataset. 
Because these model-specific trends are calculated within the same stacked dataset, they can then be compared 
using standard Wald tests. 
 
For standardization to the population of Oxfordshire in 1998, we used estimates from the UK Office for 
National Statistics. These were not available for 2016 so we used a linear extrapolation of the previous two 
years. 
 
Under 1% of susceptibility results were missing for each antibiotic tested, with the exception of trimethoprim 
for which blood cultures were not tested October-December 2014. Analyses therefore used a probability weight 
of 4/3 for the incidence of trimethoprim-resistant E. coli bacteraemias in 2014; all other analyses of incidence of 
resistant bacteraemias/UTIs were based on observed data only (i.e. complete cases). 
 
For analysis of levels of monocytes, neutrophils, lymphocytes, C-reactive protein (CRP), creatinine and urea at 
sample collection (continuous outcomes, closest value within [-2,+2] days), continuous test results were 
truncated at the 1st and 99th percentile; median values were modelled using quantile regression to avoid 
influence from outliers. All analyses of test results were restricted to complete cases; for EC-BSI completeness 
was 93% for neutrophils, 93% for C-reactive protein (CRP) (post-2000 only), 95% for creatinine and 93% for 
urea. CRP was reported with different upper thresholds over the study period, and approximately half the values 
were consistently above the upper threshold. CRP was therefore considered as a binary rather than continuous 
outcome, namely CRP≥156 mg/L (minimum upper threshold used over 1998-2016). In January 2009 the 
creatinine analysis method changed in the laboratory,3 models adjusted for this change using a step-function. 
Out-of-hospital mortality was determined by routine updates from a national information system. 1% (82/5701) 
of patients could not be linked (for example due to incomplete identifiers particularly in older historical data 
where NHS numbers were not used consistently); again analyses were restricted to complete cases where out-of-
hospital mortality was available. All analyses of laboratory parameters and 30-day mortality were adjusted for 
age and sex (which led to 5 community cases being dropped as sex was unknown). To investigate whether there 
was any evidence of differential severity in susceptible versus resistant cases, we extended these models for 30-
day mortality following EC-BSI and neutrophils at presentation with EC-BSI to additionally include a binary 
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factor for whether the EC-BSI was co-amoxiclav-resistant versus co-amoxiclav-susceptible, and the interaction 
between this factor and calendar time (as represented by exact date of blood sample collection). The interaction 
term tests whether there is any evidence that these severity markers are changing differently in co-amoxiclav-
resistant versus co-amoxiclav-susceptible EC-BSI. As there was no evidence of such heterogeneity, the 
interaction term was removed from the model and a main effect of co-amoxiclav-resistant versus co-amoxiclav-
susceptible EC-BSI on 30-day mortality following EC-BSI and neutrophils at presentation with EC-BSI 
estimated. 
 
In order to estimate a simple univariable association between hospital antimicrobial prescribing and nosocomial 
co-amoxiclav resistant bacteremia incidence, analogous to a Spearman rho for two continuous factors, we 
calculated a bivariate cross-correlation, i.e. the correlation between one series at time t and another series at time 
t - k as a function of the time t and lag k. Because of differences in the time periods in which (quarterly) 
antibiotic prescribing data were available, we included only financial years 2003-2014. For each class of 
antibiotics, and all antibiotics combined, we considered a time lag of 0 (ie same quarter), and all quarters up to -
3 and +3, (where -1/4 means antibiotic use in previous quarter against bacteraemias in current quarter). 
 
To estimate associations between annual community urine sample submission, community EC-UTI and 
community co-amoxiclav-resistant EC-UTI incidence, and co-amoxiclav use in primary care, we used 
backwards elimination to identify the most parsimonious model including co-amoxiclav defined-daily-doses 
(DDD) per 1000 registered patients in the current and previous year together with their interaction with the 
calendar year trend, adjusting for general practice and including the number of patients per primary-care facility 
per year as an offset. We did not consider co-amoxiclav resistant EC-BSI incidence as numbers were too small 
over the period where antibiotic data were available. As antibiotic usage was only available from the community 
from 2011-2016, we considered annual outcomes from 2012-2016 only. Because incidence of co-amoxiclav 
resistant EC-UTIs were lower than the predicted time trend in 2012 (Supplementary Figure 11) we allowed for 
this using a step function, and estimated time trends in addition to this. All models excluded 13 practices, 8 
which had missing data for at least one of the years and 5 which submitted less than 151 samples over 2011-
2016 (all others submitted over 308 samples). For the outcome co-amoxiclav-resistant EC-UTI, the best 
predictor was usage in the previous year and there was no evidence of interactions with the calendar time trend 
(p=0.22). For EC-UTIs and all urines, usage in the current year was the better predictor and there was no 
evidence of interactions with the calendar time trend (p=0.55). The same models were chosen when including 
all samples regardless of hospital-exposure group. We also obtained 2017 demographics from the Health and 
Social Care Information Centre and included proportion aged over 65 and proportion males per primary-care 
facility as explanatory variables, without primary-care facility.  
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Supplementary Results 
 
(a) Further details of quasi-nosocomial BSIs 
For the 1132 quasi-nosocomial EC-BSI patients discharged in the preceding 30 days, the most common reasons 
for the antecedent admission were malignancy (395,35%), gastrointestinal disorders (177,16%), and 
renal/urological disorders (164,14%) (Supplementary Table 1), with no major temporal variability 
(Supplementary Figure 1A). 
 
There was no evidence that the antecedent admission was shorter in the 1132 quasi-nosocomial EC-BSI patients 
discharged in the preceding 30 days than the quasi-community EC-BSI patients discharged 31-365 days 
previously (median 2·0 (IQR:0·3-7·9) days vs 2·3 (0·3-8·2) respectively, ranksum p=0·15).  
 
There was, however, strong evidence that quasi-nosocomial EC-BSIs with a UTI diagnostic code or an 
infectious primary diagnostic code for the antecendent admission were rising faster than those without 
(heterogeneity p=0·005, p<0·001 respectively, Supplementary Figure 1B&C), but these still comprised <25% 
of quasi-nosocomial EC-BSIs.  
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Supplementary Table 1 Primary diagnostic code for the antecedent admission for quasi-nosocomial EC-BSIs 
 
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total 
Cardiovascular disorder 1 2 3 2 2 4 3 1 4 3 8 7 5 3 13 4 2 4 4 75 
Neurological disorder 1 0 2 2 1 1 2 0 0 1 2 4 2 5 3 0 2 3 3 34 
Dermatological or rheumatological 
disorders 0 1 1 0 1 1 2 0 1 2 3 1 0 3 1 2 1 2 
1 23 
Endocrine disorder 1 1 1 0 0 0 0 0 1 0 1 0 0 0 1 2 0 1 0 9 
Gastrointestinal disorder 7 7 2 3 4 2 4 6 13 4 13 10 17 7 11 12 15 17 23 177 
Gynaecological or obstetric disorder 1 1 1 3 1 1 4 1 2 1 1 0 1 3 0 2 4 2 1 30 
Haematological disorder 1 0 0 1 2 0 1 0 0 0 2 2 3 2 4 2 0 1 0 21 
Malignancy 15 13 15 9 16 11 23 14 15 23 22 35 26 30 29 32 26 24 17 395 
Orthopaedic disorders including trauma 0 0 3 0 0 2 1 2 1 2 2 2 5 4 1 4 5 7 3 44 
Poisoning 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 3 
Renal and urological disorders 3 7 3 4 7 4 5 6 7 11 4 10 13 12 15 11 12 13 17 164 
Respiratory disorder 2 1 0 3 2 4 0 1 3 4 3 7 4 5 3 4 5 7 12 70 
Dermatological disorder 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 
Other 3 2 5 0 2 2 3 1 5 3 1 6 7 8 8 10 4 6 9 85 
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Supplementary Table 2 Summary of current (2016) annual rate ratios  
 
 Insert Community 
aRR (95% CI) 
Quasi-community  
aRR (95% CI) 
Quasi-nosocomial  
aRR (95% CI) 
Nosocomial  
aRR (95% CI) 
All EC-BSI Fig. 1 1.10 (1.07-1.13) 1.08 (1.07-1.10) 1.01 (0.97-1.04) 1.03 (1.02-1.04) 
According to previous EC-BSI      
 First EC-BSI * Supp. Fig. 1 1.10 (1.07-1.13) 1.08 (1.06-1.09) 1.06 (1.05-1.08) 1.03 (1.02-1.04) 
 Recurrent EC-BSI Supp. Fig. 1 1.11 (1.05-1.18) 1.18 (1.14-1.23) 0.93 (0.85-1.01) 1.06 (1.02-1.10) 
 Heterogeneity first vs recurrence EC-BSI  p=0.70 p<0.0001 p=0.004 p=0.14 
All blood cultures (regardless of result) Supp. Fig. 3 1.06 (1.05-1.07) 1.08 (1.07-1.09) 1.04 (1.03-1.05) 1.03 (1.02-1.04) 
 Heterogeneity EC-BSI vs all blood cultures  P=0.0006 p=0.92 p=0.05 p=0.76 
According to previous EC-UTI      
 All EC-BSI with previous EC-UTI ** Supp. Fig. 6 1.13 (1.07-1.19) 1.15 (1.11-1.18) 1.02 (0.93-1.11) 1.03 (1.01-1.05) 
 All EC-BSI with no previous EC-UTI Supp. Fig. 6 1.09 (1.06-1.13) 1.06 (1.04-1.07) 0.99 (0.95-1.03) 1.02 (1.01-1.03) 
 Heterogeneity by previous EC-UTI  p=0.66 p<0.0001 p=0.73 p=0.02 
According to previous CSU      
All EC-BSI with previous CSU Supp. Fig. 7 1.08 (1.06-1.10) 1.09 (1.08-1.11) 1.10 (1.08-1.12) 0.93 (0.86-1.01) 
All EC-BSI with no previous CSU Supp. Fig. 7 1.09 (1.06-1.13) 1.08 (1.06-1.09) 1.06 (1.04-1.07) 1.03 (1.01-1.04) 
Heterogeneity by previous CSU  p=0.61 p=0.18 P=0.0002 p=0.03 
According to co-amoxiclav susceptibility      
 Co-amoxiclav resistant EC-BSI Fig. 3 1.14 (1.11-1.17) 1.18 (1.14-1.22) 1.11 (1.05-1.17) 1.14 (1.12-1.16) 
 Co-amoxiclav susceptible EC-BSI Fig. 3 1.03 (1.02-1.04) 1.06 (1.04-1.07) 0.97 (0.93-1.00) 0.91 (0.85-0.97) 
 Heterogeneity   p<0.0001 p<0.0001 p<0.0001 p<0.0001 
30-day mortality: all EC-BSI Supp. Fig 7 0.99 (0.96-1.01) 0.99 (0.96,1.01) 0.98 (0.95,1.00) 0.98 (0.96,1.00) 
CRP >156 mg/L: all EC-BSI Supp. Fig 7 0.99 (0.98,1.01) 0.99 (0.97,1.01) 1.01 (0.98,1.03) 1.00 (0.98,1.02) 
30-day mortality: co-amoxiclav sensitive EC-BSI Supp. Fig 12† 0.98 (0.96,1.01) 0.99 (0.97,1.02) 0.97 (0.94,1.00) 0.96 (0.94,0.99) 
30-day mortality: co-amoxiclav resistant EC-BSI Supp. Fig 12† 1.00 (0.94,1.06) 0.96 (0.91,1.02) 1.00 (0.93,1.06) 0.98 (0.95,1.02) 
All EC-UTI Fig. 1 0.99 (0.98-1.00) 1.03 (1.02-1.03) 1.00 (0.98-1.01) 0.95 (0.94-0.95) 
According to previous EC-UTI      
 First EC-UTI * Supp. Fig. 2 0.96 (0.94-0.98) 0.99 (0.98-1.00) 1.01 (1.00-1.01) 0.93 (0.93-0.94) 
 Recurrent EC-UTI Supp. Fig. 2 1.04 (1.04-1.05) 1.04 (1.03-1.05) 1.01 (0.98-1.03) 0.99 (0.97-1.00) 
 Heterogeneity   p<0.0001 p<0.0001 p=0.99 p<0.0001 
All urine cultures (regardless of result) Supp. Fig. 5 0.99 (0.98-0.99) 1.01 (1.01-1.01) 1.02 (1.01-1.02) 1.02 (1.01-1.04) 
According to co-amoxiclav susceptibility      
 Co-amoxiclav resistant EC-UTI Supp. Fig. 11 1.29 (1.18-1.40) 1.25 (1.16-1.35) 1.14 (1.10-1.19) 1.21 (1.09-1.34) 
 Co-amoxiclav susceptible EC-UTI Supp. Fig. 11 0.94 (0.92-0.97) 0.99 (0.97-1.00) 0.91 (0.87-0.95) 0.87 (0.83-0.91) 
 Heterogeneity  p<0.0001 p<0.0001 p<0.0001 p<0.0001 
* First ever recorded per patient between 1998-2016; all other subsequent cases counted as recurrences 
** Any EC-UTI 3 or more days prior to the EC-BSI.  
† No evidence of heterogeneity therefore Supplementary Figure 11 shows pooled mortality trends across susceptible and resistant EC-BSI 
Note: showing annual rate ratios estimated by ISR in 2016; bold p<0.001, underline p between 0.001-0.05 
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Supplementary Table 3 Relative contribution of recurrent EC-BSIs and EC-UTIs to total numbers in 
2016 by recent hospital-exposure 
 Community 
Recurrent/total (%) 
Quasi-community  
Recurrent/total (%) 
Quasi-nosocomial  
Recurrent/total (%) 
Nosocomial  
Recurrent/total (%) 
Bacteraemias 4/163 (2%) 24/164 (15%) 17/91 (19%) 11/98 (11%) 
UTIs 4682/9464 (49%) 2003/3097 (65%) 472/885 (53%) 148/416 (36%) 
 
 
  
11 
Supplementary Table 4 Overall EC-BSI incidence trends in 2016, unadjusted and standardized to the sex 
and age population of Oxfordshire 1998 
 Community 
aRR (95% CI) 
(with breakpoint) 
Quasi-community 
aRR (95% CI) 
Quasi-nosocomial 
aRR (95% CI) 
Nosocomial 
aRR (95% CI) 
Unstandardized 1.10 (1.04-1.17) 1.08 (1.06-1.10) 1.07 (1.05-1.09) 1.03 (1.01-1.05) 
Standardized 1.09 (1.02-1.16) 1.07 (1.05-1.09) 1.06 (1.04-1.08) 1.02 (1.01-1.04) 
Percentage change in regression 
coefficient* 
10% 14% 12% 23% 
Also standardized for number of 
samples taken per month 
1.09 (1.02-1.16) 
 
1.07 (1.04-1.09) 
 
1.06 (1.04-1.08) 
 
1.02 (1.01-1.04) 
 
Percentage change in regression 
coefficient* 
9% 17% 12% 23% 
* difference in coefficients from standardised and unstandardized estimates expressed as a percentage of the 
unstandardized estimate. 
Note: only fitting a single trajectory to incidence for the quasi-nosocomial hospital-exposure group, 
approximating Figure 1. aRR=annual rate ratio per year in 2016; bold p<0.001, underline p between 0.001-0.05 
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Supplementary Table 5 First per patient EC-BSI incidence trends, unadjusted and standardized to the 
sex and age population of Oxfordshire 1998 
 Community 
aRR (95% CI) 
(with breakpoint) 
Quasi-community 
aRR (95% CI) 
Quasi-nosocomial 
aRR (95% CI) 
Nosocomial 
aRR (95% CI) 
Unstandardized 1.10 (1.03-1.17) 1.07 (1.05-1.10) 1.06 (1.04-1.08) 1.03 (1.01-1.05) 
Standardized 1.09 (1.02-1.16) 1.06 (1.04-1.08) 1.05 (1.04-1.07) 1.02 (1.00-1.04) 
Percentage change in regression 
coefficient* 
10% 15% 14% 26% 
Also standardized for samples 
taken per month 
1.09 (1.02-1.16) 
 
1.06 (1.04-1.08) 
 
1.05 (1.04-1.07) 
 
1.02 (1.00-1.04) 
 
Percentage change in regression 
coefficient* 
9% 19% 13% 28% 
* difference in coefficients from standardised and unstandardized estimates expressed as a percentage of the 
unstandardized estimate. 
Note: aRR=annual rate ratio per year in 2016; bold p<0.001, underline p between 0.001-0.05 
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Supplementary Table 6 Yearly numerators/denominators (percentages) for 30-day mortality following EC-BSI, co-amoxiclav resistant EC-BSIs and 30-day 
mortality following EC-BSI in co-amoxiclav resistant versus sensitive cases 
 
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total 
30-day mortality following EC-
BSI                   
  
 Community 11/65 
(17%) 
9/67 
(13%) 
9/79 
(11%) 
10/68 
(15%) 
7/72 
(10%) 
16/80 
(20%) 
13/73 
(18%) 
10/80 
(12%) 
21/81 
(26%) 
10/81 
(12%) 
12/84 
(14%) 
17/88 
(19%) 
10/84 
(12%) 
13/107 
(12%) 
14/112 
(12%) 
18/129 
(14%) 
18/141 
(13%) 
17/133 
(13%) 
19/160 
(12%) 
254/1858 
(14%) 
 Quasi-community 5/24 
(21%) 
8/52 
(15%) 
10/41 
(24%) 
3/32 
(9%) 
9/51 
(18%) 
6/52 
(12%) 
10/58 
(17%) 
4/33 
(12%) 
13/49 
(27%) 
11/63 
(17%) 
10/68 
(15%) 
14/69 
(20%) 
14/78 
(18%) 
14/86 
(16%) 
11/90 
(12%) 
14/109 
(13%) 
13/108 
(12%) 
24/117 
(21%) 
26/164 
(16%) 
219/1346 
(16%) 
 Quasi-nosocomial 5/34 
(15%) 
7/36 
(19%) 
8/37 
(22%) 
5/27 
(19%) 
9/38 
(24%) 
8/32 
(25%) 
10/48 
(21%) 
5/32 
(16%) 
16/53 
(30%) 
15/54 
(28%) 
9/62 
(15%) 
23/82 
(28%) 
16/83 
(19%) 
11/82 
(13%) 
12/89 
(13%) 
14/85 
(16%) 
8/76 
(11%) 
17/87 
(20%) 
19/91 
(21%) 
217/1132 
(19%) 
 Nosocomial 18/43 
(42%) 
19/60 
(32%) 
19/69 
(28%) 
14/54 
(26%) 
16/54 
(30%) 
14/65 
(22%) 
14/59 
(24%) 
20/73 
(27%) 
15/60 
(25%) 
13/77 
(17%) 
26/85 
(31%) 
17/82 
(21%) 
20/85 
(24%) 
19/83 
(23%) 
25/91 
(27%) 
18/68 
(26%) 
14/71 
(20%) 
16/86 
(19%) 
23/98 
(23%) 
340/1365 
(25%) 
Numbers of co-amoxiclav 
resistant EC-BSIs 
                    
 Community 8/72 
(11%) 
3/70 
(4%) 
9/87 
(10%) 
7/70 
(10%) 
6/74 
(8%) 
8/85 
(9%) 
9/78 
(12%) 
7/82 
(9%) 
19/86 
(22%) 
15/81 
(19%) 
16/87 
(18%) 
21/93 
(23%) 
20/88 
(23%) 
22/110 
(20%) 
17/113 
(15%) 
48/135 
(36%) 
44/144 
(31%) 
42/136 
(31%) 
46/162 
(28%) 
367/1853 
(20%) 
 Quasi-community 2/25 
(8%) 
7/51 
(14%) 
6/32 
(19%) 
5/51 
(10%) 
8/52 
(15%) 
7/58 
(12%) 
3/33 
(9%) 
18/49 
(37%) 
14/63 
(22%) 
14/68 
(21%) 
14/69 
(20%) 
18/77 
(23%) 
16/87 
(18%) 
11/90 
(12%) 
40/109 
(37%) 
46/108 
(43%) 
43/117 
(37%) 
65/164 
(40%) 
2/25 
(8%) 
337/1343 
(25%) 
 Quasi-nosocomial 5/35 
(14%) 
2/36 
(6%) 
3/37 
(8%) 
1/27 
(4%) 
1/38 
(3%) 
3/32 
(9%) 
8/48 
(17%) 
3/32 
(9%) 
11/53 
(21%) 
18/54 
(33%) 
11/63 
(17%) 
20/84 
(24%) 
36/83 
(43%) 
19/81 
(23%) 
23/89 
(26%) 
41/85 
(48%) 
27/76 
(36%) 
34/87 
(39%) 
47/91 
(52%) 
313/1131 
(28%) 
 Nosocomial 6/43 
(14%) 
8/61 
(13%) 
4/69 
(6%) 
8/53 
(15%) 
8/54 
(15%) 
8/65 
(12%) 
8/59 
(14%) 
9/73 
(12%) 
10/60 
(17%) 
23/78 
(29%) 
24/85 
(28%) 
24/82 
(29%) 
29/85 
(34%) 
25/83 
(30%) 
27/91 
(30%) 
40/68 
(59%) 
39/71 
(55%) 
42/86 
(49%) 
54/98 
(55%) 
396/1364 
(29%) 
30-day mortality following EC-
BSI: co-amoxiclav resistant 
versus sensitive                   
  
 Community resistant 1/7 
(14%) 
0/2 
(0%) 
1/7 
(14%) 
1/6 
(17%) 
1/6 
(17%) 
1/8 
(12%) 
1/9 
(11%) 
0/6 
(0%) 
3/18 
(17%) 
3/15 
(20%) 
2/16 
(12%) 
8/19 
(42%) 
1/20 
(5%) 
4/22 
(18%) 
0/17 
(0%) 
7/45 
(16%) 
6/42 
(14%) 
7/41 
(17%) 
7/44 
(16%) 
54/350 
(15%) 
 Community sensitive 10/58 
(17%) 
9/65 
(14%) 
8/71 
(11%) 
8/61 
(13%) 
6/66 
(9%) 
15/72 
(21%) 
11/63 
(17%) 
10/74 
(14%) 
18/63 
(29%) 
6/65 
(9%) 
10/68 
(15%) 
9/69 
(13%) 
9/64 
(14%) 
9/85 
(11%) 
13/94 
(14%) 
11/84 
(13%) 
12/98 
(12%) 
9/90 
(10%) 
12/115 
(10%) 
195/1425 
(14%) 
 Quasi-community resistant 0/1 
(0%) 
1/6 
(17%) 
0/0  
(-) 
0/6 
(0%) 
2/5 
(40%) 
1/8 
(12%) 
1/7 
(14%) 
0/3 
(0%) 
5/18 
(28%) 
3/14 
(21%) 
3/14 
(21%) 
3/14 
(21%) 
3/18 
(17%) 
5/16 
(31%) 
3/11 
(27%) 
4/40 
(10%) 
4/46 
(9%) 
8/43 
(19%) 
7/65 
(11%) 
53/335 
(16%) 
 Quasi-community sensitive 5/23 
(22%) 
7/45 
(16%) 
10/40 
(25%) 
3/26 
(12%) 
7/46 
(15%) 
5/44 
(11%) 
9/51 
(18%) 
4/30 
(13%) 
8/31 
(26%) 
8/49 
(16%) 
7/54 
(13%) 
11/55 
(20%) 
11/59 
(19%) 
9/70 
(13%) 
8/79 
(10%) 
10/69 
(14%) 
9/62 
(15%) 
16/74 
(22%) 
19/99 
(19%) 
166/1006 
(17%) 
 Quasi-nosocomial resistant 1/5 
(20%) 
1/2 
(50%) 
0/3 
(0%) 
0/1 
(0%) 
1/1 
(100%) 
2/3 
(67%) 
0/8 
(0%) 
0/3 
(0%) 
3/11 
(27%) 
4/18 
(22%) 
0/11 
(0%) 
5/20 
(25%) 
6/36 
(17%) 
4/19 
(21%) 
3/23 
(13%) 
10/41 
(24%) 
4/27 
(15%) 
5/34 
(15%) 
13/47 
(28%) 
62/313 
(20%) 
 Quasi-nosocomial sensitive 4/29 
(14%) 
6/34 
(18%) 
8/34 
(24%) 
5/26 
(19%) 
8/37 
(22%) 
6/29 
(21%) 
10/40 
(25%) 
5/29 
(17%) 
13/42 
(31%) 
11/36 
(31%) 
9/51 
(18%) 
18/62 
(29%) 
10/47 
(21%) 
6/62 
(10%) 
9/66 
(14%) 
4/44 
(9%) 
4/49 
(8%) 
12/53 
(23%) 
6/44 
(14%) 
154/814 
(19%) 
 Nosocomial resistant 3/6 
(50%) 
1/8 
(12%) 
1/4 
(25%) 
5/8 
(62%) 
5/8 
(62%) 
1/8 
(12%) 
3/8 
(38%) 
2/9 
(22%) 
4/10 
(40%) 
4/22 
(18%) 
6/24 
(25%) 
10/24 
(42%) 
6/29 
(21%) 
8/25 
(32%) 
9/27 
(33%) 
14/40 
(35%) 
10/39 
(26%) 
13/42 
(31%) 
12/54 
(22%) 
117/395 
(30%) 
 Nosocomial sensitive 15/37 
(41%) 
18/52 
(35%) 
18/65 
(28%) 
8/45 
(18%) 
11/46 
(24%) 
13/57 
(23%) 
11/51 
(22%) 
18/64 
(28%) 
11/50 
(22%) 
9/55 
(16%) 
20/61 
(33%) 
7/58 
(12%) 
14/56 
(25%) 
11/58 
(19%) 
16/64 
(25%) 
4/28 
(14%) 
4/32 
(12%) 
3/44 
(7%) 
11/44 
(25%) 
222/967 
(23%) 
Note: not adjusted for age and sex, in contrast to model estimates.  Mortality based on complete cases (those who could be routinely linked to national information systems, 
see Supplementary Methods). 
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Supplementary Table 7 Total number and percentage of EC-BSIs and EC-UTIs tested for each antibiotic and resistant to each antibiotic over the whole period and 
in 2016 
Bacteraemias  Tested(%) Resistant(%) Tested in 2016(%) Resistant in 2016(%) 
 Amoxicillin 5689(100%) 3357(50%) 515(100%) 294(57%) 
 Co-amoxiclav 5691(100%) 1413(20%) 515(100%) 212(41%) 
 Trimethoprim 5362(94%) 2230(35%) 515(100%) 168(33%) 
 Piptaz 5490(96%) 434(7%) 516(100%) 37(7%) 
 Gentamicin 5695(100%) 327(5%) 516(100%) 40(8%) 
 Ciprofloxacin 5694(100%) 672(10%) 516(100%) 77(15%) 
 Ceftriaxone 5474(96%) 364(5%) 516(100%) 45(9%) 
 Ceftazidime 5686(100%) 352(5%) 515(100%) 53(10%) 
 Meropenem 5555(97%) 6(0%) 516(100%) 0(0%) 
 Amikacin 1003(18%) 27(2%) 514(100%) 12(2%) 
 Aztreonam 1703(30%) 166(9%) 515(100%) 54(10%) 
 Cefalexin 844(15%) 211(22%) 0(0%) 0(NaN%) 
 Cotrimoxazole 1694(30%) 484(26%) 512(99%) 140(27%) 
 Ertapenem 2605(46%) 3(0%) 515(100%) 0(0%) 
 Fosfomycin 918(16%) 4(0%) 512(99%) 3(1%) 
UTIs      
 Amoxicillin 228183(100%) 108507(39%) 13829(100%) 6329(46%) 
 Co-amoxiclav 228054(100%) 30041(11%) 13792(99%) 3921(28%) 
 Trimethoprim 228094(100%) 97281(35%) 13825(100%) 4193(30%) 
 
Piptaz 59394(26%) 6098(8%) 13798(100%) 366(3%) 
 Gentamicin 59917(26%) 4305(6%) 13794(100%) 730(5%) 
 Ciprofloxacin 228128(100%) 14221(5%) 13826(100%) 1285(9%) 
 Ceftriaxone 55798(24%) 3830(6%) 13815(100%) 720(5%) 
 Ceftazidime 59615(26%) 4098(6%) 13815(100%) 683(5%) 
 Meropenem 59559(26%) 103(0%) 13793(100%) 6(0%) 
 Cefalexin 223197(98%) 45324(17%) 13780(99%) 1932(14%) 
 Cotrimoxazole 51033(22%) 13265(21%) 13746(99%) 3552(26%) 
 Ertapenem 51837(23%) 135(0%) 13787(99%) 32(0%) 
 Fosfomycin 50804(22%) 499(1%) 13777(99%) 90(1%) 
 Nitrofurantoin 226236(99%) 12032(4%) 13790(99%) 236(2%) 
 Pivmecillinam 28087(12%) 7514(22%) 13772(99%) 1346(10%) 
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Supplementary Table 8 Cross-correlation between hospital antimicrobial prescribing and co-amoxiclav-resistant nosocomial EC-BSI 
Antibiotic Highest absolute cross-correlation [lag (in years) at which this cross-correlation is observed]* 
Co-amoxiclav 0.75 [lag 0] 
First generation cephalosporins -0.44 [lag 3/4] 
Second generation cephalosporins -0.71 [lag 0] 
Third generation cephalosporins 0.80 [lag 0] 
Piptaz 0.62 [lag 0] 
All cephalosporins -0.59 [lag 1/4] 
Imidazole -0.51 [lag 1/4] 
Lincosamide 0.69 [lag 0] 
Macrolide -0.31 [lag -3] 
Beta lactamase resistant penicillins -0.49 [lag -2 1/4] 
Beta lactamase sensitive penicillins -0.28 [lag 1 1/4] 
Penicillins with extended spectrum -0.54 [lag 1/4] 
Quinolone -0.45 [lag -2 1/2] 
Combinations of sulfonamides and trimethoprim, including derivatives 0.35 [lag 3 1/4] 
* bivariate cross-correlation between hospital antimicrobial prescribing and nosocomial co-amoxiclav resistant bacteremia incidence, see Supplementary Methods. For each 
class of antibiotics, and all antibiotics combined, we considered a time lag of 0 (ie same quarter), and all quarters up to -3 and +3, (where -1/4 means antibiotic use in previous 
quarter against bacteraemias in current quarter, etc). The cross-correlation of largest absolute magnitude is shown. 
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Supplementary Figure 1. Annual quasi-nosocomial EC-BSIs according to the previous diagnostic code. 
 
Footnote: (A) the three main categories of primary diagnostic codes for the antecedent admission, (B) having a UTI in any of the diagnostic codes of the previous admission to 
the EC-BSI, and (C) having the primary diagnostic code of the previous admission as an infection versus non-infection. See Supplementary Table 5 for all diagnostic code 
categories.
17 
Supplementary Figure 2. Monthly EC-BSI according to recent hospital-exposure (A) first per patient only (B) recurrences within a patient only. 
 
Footnote: IRR=annual incidence rate ratio in 2016, that is the relative increase in rate per year as estimated in 2016. See Table 1 for heterogeneity tests between first vs 
subsequent EC-BSIs. 
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Supplementary Figure 3. Monthly EC-UTIs according to recent hospital-exposure (A) first per patient only (B) recurrences within a patient only. 
 
Footnote: IRR=annual incidence rate ratio in 2016, that is the relative increase in rate per year as estimated in 2016. See Table1 for heterogeneity tests between first vs 
subsequent EC-UTIs. 
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Supplementary Figure 4. Monthly blood samples submitted for culture regardless of result according to recent hospital-exposure (first and repeat samples per 
patient). 
 
Footnote: including repeat samples submitted >14 days after an index sample. IRR=annual incidence rate ratio in 2016, that is the relative increase in rate per year as 
estimated in 2016.  
20 
Supplementary Figure 5. Trends in haematology/biochemistry test results and 30-day mortality following a blood culture being taken regardless of its result 
according to recent hospital-exposure (first and recurrent infections). 
 
Footnote: including repeat samples submitted >14 days after an index sample. Fitted lines are for men (blue) and women (red) at mean age, IRR=annual rate ratio in 2016, 
that is the relative increase in rate per year as estimated in 2016. CM=change in median in 2016  
21 
Supplementary Figure 6. Monthly urine samples submitted for culture regardless of result according to recent hospital-exposure (first and repeat samples per 
patient). 
 
Footnote: including repeat samples submitted >90 days after an index sample. IRR=annual incidence rate ratio in 2016, that is the relative increase in rate per year as 
estimated in 2016.
22 
Supplementary Figure 7. Trends in haematology/biochemistry test results and 30-day mortality following 
EC-BSI according to recent hospital-exposure (first and recurrent infections). 
 
 
Footnote: CM=change per year in median value in 2016, that is the relative increase in rate per year as estimated 
in 2016. Adjusted for age and gender. Fitted lines are for men (blue) and women (red) at mean age, IRR=annual 
rate ratio in 2016.
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Supplementary Figure 8. EC-BSIs: whether (A) patient had had an EC-UTI ≥3 days previously (B) 
patient had not had an EC-UTI ≥3 days previously (C) EC-BSIs according to time from previous EC-UTI.  
 
 
Footnote: C: had had an EC-UTI 3-30 days previously, 31 to 365 days previously, more than 365 days 
previously, or never. IRR=annual incidence rate ratio in 2016, that is the relative increase in rate per year as 
estimated in 2016. See Supplementary Table 1 for heterogeneity tests between patients with and without an EC-
UTI ≥3 days previously. Results similar restricting to EC-UTIs within the last year or 4 years. 
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Supplementary Figure 9. EC-BSIs: whether (A) patient had had a catheter urine specimen (CSU) 
previously (B) patient had not had a CSU previously (C) EC-BSIs according to time from previous CSU. 
Footnote: C: had had a CSU in the previous 2 days, 3-30 days previously, 31 to 365 days previously, more than 
365 days previously, or never. IRR=annual incidence rate ratio in 2016, that is the relative increase in rate per 
year as estimated in 2016. See Supplementary Table 1 for heterogeneity tests between patients with and without 
a CSU previously.   
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Supplementary Figure 10. Annual EC-BSIs according to recent hospital-exposure and antibiotic 
susceptibility (A) by antibiotic, (B) summary. 
(A) by antibiotic 
  
26 
(B) summary 
 
Footnote: IRR=annual incidence rate ratio in 2016, that is the relative increase in rate per year as estimated in 
2016.  
27 
Supplementary Figure 11. Annual EC-UTIs according to recent hospital-exposure and antibiotic 
susceptibility.  
 
 
Footnote: IRR=annual incidence rate ratio in 2016, that is the relative increase in rate per year as estimated in 
2016.
28 
Supplementary Figure 12: Severity of co-amoxiclav-resistant vs susceptible EC-BSIs, by (A) neutrophil counts and (B) 30-day mortality across hospital exposure 
groups.  
 
Footnote: CM=change per year in median value in 2016. Fitted lines are for co-amoxiclav susceptible women (red and dashed), co-amoxiclav susceptible men (blue and 
dashed), co-amoxiclav resistant women (red and solid), and co-amoxiclav resistant men (blue and solid) at mean age. IRR=annual rate ratio in 2016, that is the relative 
increase in rate per year as estimated in 2016. Neutrophils and mortality are both also adjusted for age and sex. No evidence of different trends between co-amoxiclav 
susceptible and co-amoxiclav resistant for either neutrophils (pheterogeneity>0.67) or 30-day mortality (pheterogeneity>0.35). 
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Supplementary Figure 13. Co-amoxiclav-resistant EC-UTIs (A), EC-UTIs (B) and urine samples submitted regardless of result (C), per 1000 patients per primary-
care facility 2012-2016 compared with co-amoxiclav usage. 
 
Footnote: showing one record per year per primary-care facility. For (A) the strongest predictor was co-amoxiclav DDD per 1000 patients per general practice in the previous 
year; for (B) and (C) the strongest predictor was co-amoxiclav DDD per 1000 patients per general practice in the current year. Spearman rho (and models) for each panel 
excludes 5 facilities which submitted less than 151 samples over 2011-2016 (all others submitted over 300). Spearman rho univariable associations with  previous vs current 
co-amoxiclav usage for the 3 outcomes left to right =0.2 vs =0.05, =0.36 vs =0.38, =0.38 vs =0.41 respectively.
30 
 
Supplementary Figure 14: Co-amoxiclav resistance in EC-BSIs according to different testing methods 
 
 
Footnote: DD=disc diffusion. MIC=median inhibitory concentration by microbroth dilution (Phoenix) 
